Bevacizumab in Treating Young Patients With Refractory Solid Tumors

Conditions

• Unspecified Childhood Solid Tumor, Protocol Specific

Eligibility Criteria

Sex

ALL

Age

1 Year - 21 Years

Healthy Volunteers

Not accepted

Interventions

• bevacizumab — BIOLOGICAL
  Given IV

Study Details

This phase I trial is studying the side effects and best dose of bevacizumab in treating young patients with refractory solid tumors. Monoclonal antibodies, such as bevacizumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

Key Dates

First listed

Jun 11, 2004

Start date

Dec 31, 2003

Status verified

Jun 2013

Primary completion

Oct 31, 2005

Study Design

Enrollment

24 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Arm I
  Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Maximum tolerated dose defined based on the dose-limiting toxicities graded according to Common Terminology Criteria for Adverse Events v3.0 [ Time Frame: 28 days ]

Locations (1)

Find similar trials in Arcadia, CA

Related Studies

• Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
  Recruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina